Breaking News

Nomura, MUFJ-MS, Goldman, JPMorgan to Lead Japan Post IPO
Tweet TWEET

The Zacks Analyst Blog Highlights: Merrimack Pharmaceuticals, Bristol-Myers Squibb, Sanofi, Novo Nordisk and Hewlett-Packard

 The Zacks Analyst Blog Highlights: Merrimack Pharmaceuticals, Bristol-Myers
               Squibb, Sanofi, Novo Nordisk and Hewlett-Packard

PR Newswire

CHICAGO, March 21, 2013

CHICAGO, March 21, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Merrimack Pharmaceuticals, Inc.
(Nasdaq:MACK), Bristol-Myers Squibb (NYSE:BMY), Sanofi (NYSE:SNY), Novo
Nordisk (NYSE:NVO) and Hewlett-Packard Company (NYSE:HPQ).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday's Analyst Blog:

Sanofi/Merrimack Candidate Progresses

Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) recently announced that it has
completed the enrollment process for a phase II trial on its oncology
candidate, MM-121. The phase II trial is designed to evaluate the efficacy of
MM-121 in combination with Bristol-Myers Squibb's (NYSE:BMY) Taxol
(paclitaxel) in advanced ovarian cancer patients who are platinum-resistant or
platinum refractory. Merrimack is collaborating with Sanofi (NYSE:SNY) for
MM-121.

The open-label, randomized phase II trial is designed to evaluate the efficacy
of MM-121 in combination with Taxol versus Taxol alone in 223 patients
enrolled in the US and Europe. The primary endpoint of the trial is
progression-free survival (PFS). Merrimack expects that top-line data from the
phase II trial will be released in the second half of 2013.

MM-121 is also being evaluated for other oncology indications including
hormone sensitive breast cancer, non-small cell lung cancer (NSCLC) and HER2
negative neoadjuvant breast cancer.

We note that Merrimack and Sanofi inked an exclusive global licensing
agreement in Oct 2009 for the development and co-commercialization of MM-121.
Under the terms of the agreement, for each indication, Merrimack will be
responsible for the development of MM-121 till phase II proof-of-concept.
Thereafter Sanofi will take up development and commercialization activities.
Merrimack has the right to co-promote MM-121in the US, following its approval.

Sanofi carries a Zacks Rank #3 (Hold) in the short run, while Merrimack
carries a Zacks Rank #4 (Sell). Right now, Novo Nordisk (NYSE:NVO) looks more
attractive in the pharma space with a Zacks Rank #2 (Buy).

H-P Focuses on Analytics Business

After strengthening its position in the personal computing, server and cloud
computing segments, HP Enterprise Management & Analytics, a division of
Hewlett-Packard Company (NYSE:HPQ), has recently rolled out a service
specially targeted at its enterprise clients. The service is intended to
manage and evaluate the Big Data generated by them.

This is a new line of business for HP, which will help it generate additional
revenue, as it has the potential to improve efficiency, reduce risk and lower
the cost structure of customers.

After a detailed research of the information and data analysis market, HP
found that more than one out of two business executives of different companies
were of the opinion that their organizations did not have the tools to glean
business insights from the huge amounts of data they were generating. This
prompted HP to develop technology that could help companies discover this
information.

The study also found that companies have lacked the expertise and strategy to
properly manage their database.

HP has understood the fact that with better management and analysis of data,
companies can efficiently manage their customers.After identifying this spot,
HP seeks to address the situation with new solutions. 

As per a recent research report published by the technology research firm
Gartner, the global analytics and business intelligence market is expected to
grow 7.0% in 2013. Though this growth rate seems decent, it is low compared
with the 16.0% growth estimated for 2011. While analyzing the growth rate, we
have to keep in mind the recent recessionary phase, which the world economy is
going through.

Gartner also expects the growth rate to remain in the single-digit range for
the next few years. At the end of 2013, the analytics and business
intelligence market will remain at $14 billion and grow to $17 billion by
2016.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.